Drug Interaction Study With a Potential Alzheimer's Disease Compound
Status:
Completed
Trial end date:
2008-10-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine whether BMS-708163 will effect the pharmacokinetics
of the commonly prescribed medicines midazolam, warfarin, caffeine,omeprazole and
dextromethorphan
Phase:
Phase 1
Details
Lead Sponsor:
Bristol-Myers Squibb
Treatments:
Caffeine Dextromethorphan Midazolam Omeprazole Vitamin K Vitamins Warfarin